Cosmetic cross-reference Noindex: medium evidence

Salai, ext.

CAS 97952-72-2

Salai, ext. (CAS 97952-72-2) is a pharmaceutical compound with 0 bioactivity targets and 3 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
3
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EPA DSSTox

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Salai, ext.
CAS Number
97952-72-2
Source Match
EPA DSSTox
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE DSSTox identifiers DTXSID101043622

Cross-Reference to Chemicals

Same-CAS substance identity is available in the industrial chemicals vertical.

Salai, ext. is linked to DTXSID101043622 in DSSTox identifiers.

View industrial chemical data →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Salai, ext. used for in pharmaceutical contexts?

Salai, ext. (CAS 97952-72-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Salai, ext.?

Salai, ext. has 3 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Injection site bruising, Off label use, Product storage error. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Salai, ext. also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Boswellia Serrata Extract with EU status "permitted".

What clinical phase is Salai, ext. in?

No phase 1-4 clinical development badge is rendered for Salai, ext. because the matched compound identifier rows do not contain a max-phase value.